EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

The small molecule fibroblast growth factor receptor inhibitor infigratinib exerts anti‐inflammatory effects and remyelination in a model of multiple sclerosis

Ranjithkumar Rajendran, Vinothkumar Rajendran iD, Gregor Böttiger, Christine Stadelmann, Kian Shirvanchi, Laureen von Au, Sudhanshu Bhushan, Natascha Wallendszus, Darja Schunin, Victor Westbrock, Gerhard Liebisch, Süleyman Ergün and 2 more

British Journal of Pharmacology · 2023-12 · 180 (23) · 2989-3007

DOI: 10.1111/bph.16186 ↗

At a glance

Journal article in British Journal of Pharmacology, published online on 2023-07-31. Written by Ranjithkumar Rajendran and 13 co-authors. Institution: Experimental Neurology Group, Department of Neurology, University of Giessen, Giessen, Germany. Major MEDLINE topics: Multiple Sclerosis, Encephalomyelitis, Autoimmune, Experimental, Remyelination. Cited 16 times so far (Crossref); 62 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose Fibroblast growth factors and receptors (FGFR) have been shown to modulate inflammation and neurodegeneration in multiple sclerosis (MS). The selective FGFR inhibitor infigratinib has been shown to be effective in cancer models. Here, we investigate the effects of infigratinib on prevention and suppression of first clinical episodes of myelin oligodendrocyte glycoprotein (MOG) 35–55 ‐induced experimental autoimmune encephalomyelitis (EAE) in mice. Experimental Approach The FGFR inhibitor infigratinib was given over 10 days from the time of experimental autoimmune encephalomyelitis induction or the onset of symptoms. The effects of infigratinib on proliferation, cytotoxicity and FGFR signalling proteins were studied in lymphocyte cell lines and microglial cells. Key Results Administration of infigratinib prevented by 40% and inhibited by 65% first clinical episodes of the induced experimental autoimmune encephalomyelitis. In the spinal cord, infiltration of lymphocytes and macrophages/microglia, destruction of myelin and axons were reduced by infigratinib. Infigratinib enhanced the maturation of oligodendrocytes and increased remyelination. In addition, infigratinib resulted in an increase of myelin proteins and a decrease in remyelination inhibitors. Further, lipids associated with neurodegeneration such as lysophosphatidylcholine and ceramide were decreased as were proliferation of T cells and microglial cells. Conclusion and Implications This proof of concept study demonstrates the therapeutic potential of targeting FGFRs in a disease model of multiple sclerosis. Application of oral infigratinib resulted in anti‐inflammatory and remyelinating effects. Thus, infigratinib may have the potential to slow disease progression or even to improve the disabling symptoms of multiple sclerosis.

Subjects

MeSH terms (MEDLINE)

Multiple SclerosisEncephalomyelitis, Autoimmune, ExperimentalRemyelinationMiceAnimalsSpinal CordMyelin-Oligodendrocyte GlycoproteinAnti-Inflammatory AgentsReceptors, Fibroblast Growth FactorMice, Inbred C57BLPhenylurea CompoundsPyrimidines

Author keywords

Experimental autoimmune encephalomyelitisFGFRinfigratinibmultiple sclerosisneuroinflammationremyelination

Substances

Myelin-Oligodendrocyte GlycoproteinAnti-Inflammatory AgentsReceptors, Fibroblast Growth FactorinfigratinibPhenylurea CompoundsPyrimidines

Authors and institutions

  • Experimental Neurology Group, Department of Neurology, University of Giessen, Giessen, Germany.
  • Institute of Neuropathology, University Medical Center Göttingen, Göttingen, Germany.
  • Institute for Anatomy and Cell Biology, University of Giessen, Giessen, Germany.
  • Institute of Clinical Chemistry and Laboratory Medicine, University Hospital of Regensburg, Regensburg, Germany.
  • Institute of Anatomy and Cell Biology, University of Würzburg, Würzburg, Germany.

ORCID profiles: Vinothkumar Rajendran

Cite

APA

Rajendran, R., Rajendran, V., Böttiger, G., Stadelmann, C., Shirvanchi, K., von Au, L., Bhushan, S., Wallendszus, N., Schunin, D., Westbrock, V., Liebisch, G., Ergün, S., Karnati, S., & Berghoff, M. (2023). The small molecule fibroblast growth factor receptor inhibitor infigratinib exerts anti‐inflammatory effects and remyelination in a model of multiple sclerosis. British Journal of Pharmacology, 180(23), 2989-3007. https://doi.org/10.1111/bph.16186

Vancouver

Rajendran R, Rajendran V, Böttiger G, Stadelmann C, Shirvanchi K, von Au L, et al. The small molecule fibroblast growth factor receptor inhibitor infigratinib exerts anti‐inflammatory effects and remyelination in a model of multiple sclerosis. British Journal of Pharmacology. 2023;180(23):2989-3007. doi:10.1111/bph.16186

BibTeX
@article{Rajendran2023,
  author = {Rajendran, Ranjithkumar and Rajendran, Vinothkumar and Böttiger, Gregor and Stadelmann, Christine and Shirvanchi, Kian and von Au, Laureen and Bhushan, Sudhanshu and Wallendszus, Natascha and Schunin, Darja and Westbrock, Victor and Liebisch, Gerhard and Ergün, Süleyman and Karnati, Srikanth and Berghoff, Martin},
  title = {The small molecule fibroblast growth factor receptor inhibitor infigratinib exerts anti‐inflammatory effects and remyelination in a model of multiple sclerosis},
  journal = {British Journal of Pharmacology},
  year = {2023},
  volume = {180},
  number = {23},
  pages = {2989--3007},
  doi = {10.1111/bph.16186}
}
Start for free →